Status:

COMPLETED

Multiple Dose ASM8 in Mild Asthmatics

Lead Sponsor:

Syntara

Conditions:

Asthma

Eligibility:

All Genders

18-65 years

Phase:

PHASE1

PHASE2

Brief Summary

To determine the safety and efficacy of multiple doses of ASM8 antisense oligonucleotides in asthmatics.

Detailed Description

This is a double-blind, placebo-controlled, crossover trial to evaluate the safety, tolerability and efficacy of inhaled ASM8 for the treatment of allergen-induced asthma. Individuals with stable, mil...

Eligibility Criteria

Inclusion

  • Part 1: Men and women 18 to 65 years of age; generally good health; mild to moderate, stable, allergic asthma as defined by ATS criteria (1); history of episodic wheeze and shortness of breath; forced expiratory volume in 1 second (FEV1) at baseline ≥70% of the predicted value; able to comprehend and follow all required study procedures; willing and able to sign an informed consent form.
  • Part 2: Methacholine challenge at baseline (PC20 ≤16 mg/mL); positive skin-prick test to common aeroallergens (cat, dust mite, grass, pollen) and positive allergen-induced early and late airway bronchoconstriction.

Exclusion

  • Part 1 and Part 2: Significant acute or chronic medical or psychiatric illness; known coagulopathy, worsening of asthma or respiratory infection in the preceding 6 weeks; use of inhaled or oral corticosteroids within the last 28 days, antihistamines, immunosuppressives, nonsteroidal anti-inflammatory drugs, or anticoagulants (intermittent doses of short-acting β2-agonist are allowed); use of medications that may interact with ASM8; investigational drug use within 30 days; any clinically significant abnormality on screening laboratory determinations; current tobacco use in previous 3 months or 10 pack-years; pregnant or lactating women; women actively seeking pregnancy or who are not using adequate contraception; history of serious adverse effect (SAE) or hypersensitivity to any drug; 20% decrease in FEV1 or FVC with baseline saline in methacholine challenge during screening.

Key Trial Info

Start Date :

December 1 2005

Trial Type :

INTERVENTIONAL

End Date :

April 1 2006

Estimated Enrollment :

15 Patients enrolled

Trial Details

Trial ID

NCT00264966

Start Date

December 1 2005

End Date

April 1 2006

Last Update

December 3 2012

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

McMaster University

Hamilton, Ontario, Canada, L8N 3Z5

2

Hopital Laval

Ste-Foy, Quebec, Canada, G1V 4G5

3

Saskatoon Hospital

Saskatoon, Saskatchewan, Canada, S7N 0W8